|
Is the incidence and prevalence of inhibitors greater
with recombinant products? No
J . M. LUSHER
Division of Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI, USA
To cite this article: Lusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost 2004; 2:
863–5.
See also Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. This issue, pp 861–2.
原文下载：重组凝血因子是否更易产生抑制物？不是
|
